Biotech | March 12, 2022
BioPharma’s Herceptin biosimilar Phase 3 results positive
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The money will be donated to the United Nations Children’s Fund (UNICEF)
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
High level of vaccine efficacy maintained over a 6-month period of surveillance
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Subscribe To Our Newsletter & Stay Updated
